SPOTLIGHT: Draxis inks J&J deal


Contract manufacturer Draxis Pharma has just inked a new deal with Johnson & Johnson to make a variety of products through 2013. The contract includes a two-year ramp-up period and five years of commercial production estimated at $120 million. The deal will mean up to 100 new jobs for Draxis in the Montreal area, including 50 new workers at a brand-new facility. Release

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.